tbuckley/cabot-search huggingface dataset:
Virginia Health Bulletin, 1916.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
Authors: Nathan Hale Fowler, Wolfgang Hiddemann, John Leonard, Julie S. Larsen, Esther Rose, Sen Hong Zhuang, Jessica Vermeulen, Steven Sun, Lisa Mentzer, Tzu-Min Yeh, Gilles A. Salles
Journal: Journal of Clinical Oncology (2015)

TPS8601 Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non-Hodgkin lymphomas (iNHL) and account for approximately 22% and 10%, respectively, of all NHLs. Although patients (pts) often respond to initial therapy, most relapse and suffer substantial morbidity and mortality related to persistence/recurrence of disease. For pts with relapsed iNHL, the most common chemoimmunotherapy regimens are BR and R-CHOP; however, outcomes in the relapsed setting remain suboptimal. Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated activity in a phase 1 study in pts with various B-cell malignancies, including iNHL. A phase 2 monotherapy study in chemoimmunotherapy-resistant FL is ongoing. Other studies have demonstrated that ibrutinib can be safely combined with BR or R-CHOP. Based on these observations, this phase 3 trial has been designed to investigate the combination of ibrutinib with BR or R-CHOP in pts with iNHL. Methods: The SELENE study, PCI32765FLR3001, is a randomized, double-blind, placebo-controlled, multicenter phase 3 study of ibrutinib combined with either BR or R-CHOP for previously treated FL or MZL. The study aims to enroll approximately 400 pts with disease that has relapsed, or was refractory to, prior chemoimmunotherapy. All pts will receive 6 cycles of BR or R-CHOP (based on prior treatment) and either daily oral 560 mg ibrutinib or placebo continued up to progression. The primary objective is to evaluate whether the addition of ibrutinib to BR or R-CHOP will prolong progression-free survival; secondary objectives were evaluation of OS, CR rate, ORR, patient-reported lymphoma symptoms, and safety. Exploratory objectives include minimal residual disease negative rate in FL pts, patient-reported outcomes related to general health status, and the pharmacokinetics of ibrutinib. Approximately 145 sites in Europe, Asia, Australia, USA and South America will participate. Enrollment began in Q1 2014. As of January 8, 2015, 163 pts have been randomized across 76 sites in 16 countries. Clinical trial information: NCT01974440.
THE TONSILS IN CHILDHOOD
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic and therapeutic technology assessment. Ureteral stone management: the use of ureteroscopy with extracorporeal shockwave lithotripsy or ultrasonic lithotripsy
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Walter Somerville
Authors: Walter Somerville
Journal: BMJ (2005)

Walter Somerville assisted at the UK's first cardiac catheterisation, performed by Paul Wood in 1948.For 20 years he edited the British Heart Journal, now simply Heart.He was consultant cardiologist at Harefield Hospital and the Middlesex Hospital, and senior lecturer at the Middlesex for 25 years, and was crucial to the success of cardiac surgery at both centres.During the second world war he worked on chemical and biological weaponry, and remained on related committees for 20 years afterwards.Walter Somerville was born in Dublin.From the Jesuit Belvedere College he went to University College Dublin, doing his clinical studies at the Mater
Investigating parent of origin effects (POE) and anticipation in Irish Lynch syndrome kindreds.
Authors: Michael P. Farrell, David J. Hughes, Jasmin Schmid, Philip S. Boonstra, Bhramar Mukherjee, Margaret B. Walshe, Padraic M. Mac Mathuna, David J. Gallagher
Journal: Journal of Clinical Oncology (2013)

431 Background: Genetic diseases associated with dynamic mutations often display parent-of-origin effects (POEs) in which the risk of disease depends on the sex of the parent from whom the disease allele was inherited. Genetic anticipation describes the progressively earlier onset and increased severity of disease in successive generations of a family. Previous studies have provided limited evidence for and against both POE effect and anticipation in Lynch syndrome. We sought evidence for a specific POE effect and anticipation in Irish Lynch syndrome families. Methods: Affected parent-child pairs (APCPs) (N = 53) were evaluated from kindreds (N = 20) from two hospital-based registries of MMR mutation carriers. POE were investigated by studying the ages at diagnosis in the offspring of affected parent-child pairs. Anticipation was assessed using the bivariate Huang and Vieland model. Results: Paired t-test revealed anticipation with children developing cancer mean 11.8 years earlier than parents, and 12.7 years using the Veiland and Huang bivariate model (p &lt; 0.001). Conclusions: These data demonstrate a similar age at diagnosis among all offspring of affected mothers that was indistinguishable from affected fathers. Affected sons of affected mothers were diagnosed with cancer almost 3 years younger than female offspring; however, this finding failed to reach statistical significance. Genetic anticipation was present in this cohort of LS families, emphasizing the importance of early-onset screening. An additional 60 LS kindreds are under review and updated data will be presented at the meeting. [Table: see text]
Abstract 2726: Functional multiomic profiling identifies Aurora kinase inhibition as a therapeutic strategy in <i>RIT1</i>-mutant lung adenocarcinoma
Authors: Athea Vichas, Naomi T. Nkinsi, Alice Berger
Journal: Cancer Research (2019)

Abstract Treatment of lung cancer is evolving from standard cytotoxic to personalized treatment based on the molecular alterations unique to each patient’s tumor. In our recent work with TCGA and others, we identified somatic mutations in the gene encoding the RAS-related small GTPase, RIT1, in lung adenocarcinomas. In addition, somatic RIT1 mutations have also been identified in myeloid malignancies and germline RIT1 mutations are found in the developmental “RAS-opathy,” Noonan syndrome. In all these diseases, RIT1 mutations are mutually-exclusive with other RAS/MAPK pathway mutations, including mutations in EGFR, KRAS, and ALK. While our previous work demonstrated that gain-of-function RIT1 mutations induce activation of PI3K and MEK signaling, the specific effectors used by RIT1 to promote tumorigenesis are unknown. To genetically dissect the signaling pathways downstream of RIT1, KRAS, EGFR, and PIK3CA, we performed genome-wide CRISPR/Cas9 screens in four isogenic lung adenocarcinoma cell lines in which cell survival is dependent on the expression of the oncogene. Through integrative analysis of essential genes across the four cell lines, we identified synthetic lethal relationships unique and shared in each isogenic background. Among the dependencies identified was the requirement of aurora kinase pathway genes for survival of RIT1-mutant cells, raising the possibility of therapeutic aurora kinase inhibition in RIT1-positive tumors. To evaluate whether the dependence on Aurora kinases extended to small molecule inhibition, we performed a screen of 160 small molecules in clinical development or approved by the FDA. Consistent with our CRISPR/Cas9 results, we find that RIT1-mutant cells depend on Aurora kinase activity for survival. Interestingly, global phosphoproteomic profiling identified RIT1 regulation of an Aurora kinase-Haspin axis. Taken together these results identify a new arm of RIT1 signaling and nominate Aurora kinase inhibition as a potential therapeutic strategy in RIT1-mutated tumors. Citation Format: Athea Vichas, Naomi T. Nkinsi, Alice Berger. Functional multiomic profiling identifies Aurora kinase inhibition as a therapeutic strategy in RIT1-mutant lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2726.
The Genetics of Major Depression
Authors: Jonathan Flint, Kenneth S. Kendler
Journal: Neuron (2014)

(Neuron 81, 484–503; February 5, 2014) The original publication contained errors in gene nomenclature in Table 2. The table has now been corrected in the article online. The Genetics of Major DepressionFlint et al.NeuronFebruary 05, 2014In BriefGenetic analysis of major depression lags behind that of other disease. Genome-wide association and linkage results provide constraints on major depression’s genetic architecture, indicating that candidate gene studies are underpowered. The disorder is heterogeneous; subtypes likely exist that represent more homogenous conditions suitable for genetic dissection. Full-Text PDF Open Access
The impact of specific toy warning labels
Authors: J. A. Langlois
Journal: JAMA (1991)

According to the 1980 Consumer Product Safety Commission's small parts standard, toys with small parts that pose a choking hazard cannot be marketed for children under the age of 3 years. To comply with the standard, toy manufacturers place age labels on packaging to indicate the ages for which toys with small parts are recommended. We conducted a survey of 199 toy buyers to determine the degree to which they understood such labels as warnings and whether more explicit warning labels would affect toy buyers' willingness to purchase toys with small parts for children between 2 and 3 years of age. Forty-four percent of respondents said they would buy for a child between 2 and 3 years of age a toy with the label "Recommended for 3 and up"; only 5% said they would buy for a young child a toy with the label "Not recommended for below 3—small parts." These findings indicate that a change in the small parts standard to require more specific labeling might substantially reduce potentially hazardous toy purchases. (<i>JAMA</i>. 1991;265:2848-2850)
Treatment choices for hypertriglyceridemia
Authors: W. E. Connor
Journal: JAMA (1990)

In clinical practice, the question of what treatment to employ for the patient with slightly increased plasma cholesterol concentration and mild hypertriglyceridemia frequently arises. Such patients are certainly coronary-prone.<sup>1,2</sup>Not only do they have cholesterol and triglyceride abnormalities, but they also have decreased plasma high-density lipoprotein and increased apoprotein B levels.<sup>3</sup>These factors all enhance coronary risk. A variety of treatments are now available for such patients either before or after coronary heart disease has developed. All authorities are agreed that the first line of treatment is dietary.<sup>4,5</sup>These patients are invariably over-weight and are consuming the typical high-fat American diet. Their fat storage is usually abdominal or visceral, especially in the men. This "apple" body configuration predisposes to coronary disease since mobilization of fatty acids from visceral fat moves directly into the liver via the portal vein, where this influx stimulates the overproduction of triglyceride, very
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
Authors: Arjun Vasant Balar, Matt D. Galsky, Yohann Loriot, Nancy Ann Dawson, Andrea Necchi, Sandy Srinivas, Richard Wayne Joseph, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Alexandra Drakaki, Ignacio Duran, Jonathan E. Rosenberg, Thomas Powles, Jean H. Hoffman-Censits, Na Cui, Sanjeev Mariathasan, Ann Christine Thastrom, Oyewale O. Abidoye, Dean F. Bajorin
Journal: Journal of Clinical Oncology (2016)

LBA4500 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Sunday, June 5, 2016, and in the Annual Meeting Proceedings online supplement to the June 20, 2016, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Control by Drugs of Renal Potassium Handling
Authors: H Vel quez
Journal: The Annual Review of Pharmacology and Toxicology (1986)

Heme oxygenases (HO) catabolize free heme, that is, iron (Fe) protoporphyrin (IX), into equimolar amounts of Fe2+, carbon monoxide (CO), and biliverdin. The stress-responsive HO-1 isoenzyme affords protection against programmed cell death. The mechanism ...Read More
Cardiac revascularization
Authors: R. J Vecht
Journal: Journal of the Royal Society of Medicine (2005)

Erdheim-Chester diseaseDr Lee and his colleagues (April 2005 JRSM 1 ) describe a case of renal failure in which the radiographic appearance of bone pointed to Erdheim-Chester disease, a histiocytosis.Among the organs affected in this condition they mention pericardium.We think it important to emphasize the frequency with which heart, pericardium and great vessels are affected.Recording 6 new patients with cardiovascular involvement, Haroche et al. 2 have reviewed all 178 reported cases of Erdheim-Chester disease.56% had periaortic fibrosis, 44% pericardial infiltration and/or effusions and 31% myocardial infiltration.Interestingly, 6 patients had a right atrial myxoma.Of the 58 patients with follow-up data, 31% died from cardiovascular complications.
From the editors
Authors: Nicola Mccarthy, Gemma Alderton, Sarah Seton-Rogers, Teresa Villanueva Assistant, Meera Swami, Catriona Rodwell, Man Tse, Lewis Packwood, Lara Crow, Susanne Harris, Vicky Summersby, Patrick Managing, Judith Shadwell, Simon Fenwick Production Controller, Natalie Smith Editorial Assistants, Jacques Smit, Laura Corns, Deborah Anthony, Marketing Managers, Tim Redding, Leah Rodriguez
Journal: Nature reviews. Cancer (2010)
Testing two scales to measure sleep disturbance in people with eczema
Journal: British Journal of Dermatology (2020)

People with atopic dermatitis (AD) often find it hard to sleep, and these sleep disturbances are caused by itch, skin pain and other AD symptoms. Sleep disturbance is an important domain to be monitored in clinics, and in trials, for example when new treatments are tested or different treatments compared. Different measures are used to asses someone’s sleep disturbance, but there is limited data to support the validity of any of these measures of sleep disturbance in AD patients.
Biochemical studies with preserved transplanted canine liver
Authors: H. Brown
Journal: JAMA (1966)

The problem of hepatic transplantation is complicated by present inability to preserve donor livers until needed. If liver transplantation is in fact to play a role in treatment of hepatic disease, methods for prolonged liver preservation must be found. In the laboratory, fresh canine liver when homotransplanted will function at near normal levels for a year or more.<sup>1</sup>During transplantation, however, time without circulation must usually be less than an hour. If the time is extended beyond this, the canine liver usually suffers irreversible damage. Studies with the pig liver show it is somewhat more hardy in that it will perform biochemical functions at normal or near normal levels for several hours after removal,<sup>2</sup>but it is still not known whether after this period such livers when transplanted will maintain an animal. Several methods for preservation of heart, lung, intestine, kidney,<sup>3,4</sup>and ovary<sup>5</sup>have been intensively
THE BEHAVIOR OF STRONTIUM IN THE BODY
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Any Questions
Journal: BMJ (1979)

General practitioners are slow, however, to change their practice.Little careful research is done in general practice and many new developments are introduced without being evaluated.Vocational training, health centres, and practice teams have all been introduced without any work showing that standards are raised, morbidity and mortality reduced, and the service improved."Most of these changes are very expensive and their value should be shown.Nobody knows what goes on in general practice," summed up Dr Primus.Running costs of practice "I could run a practice with only a stethoscope and a roof over my head.I'm not advocating such minimal conditions but pointing out that receptionists, nurses, electrocardiographs, typewriters, and such like are by no means essential."Dr Primus's practice employs a practice manager, five receptionists (most of them part time), and a nurse; a second nurse and a health visitor are also attached to the practice.When Dr Primus first started in practice many years ago he looked after exactly the same number of patients as now but without any ancillary helpers apart from the district nurse.Of course, he says, people will say that the work load has increased, but he thinks that
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver
Authors: Kazuaki Miyake, Wataru Ogawa, Michihiro Matsumoto, Takehiro Nakamura, Hiroshi Sakaue, Masato Kasuga
Journal: Journal of Clinical Investigation (2002)

The physiological relevance of phosphoinositide 3-kinase (PI 3-K) signaling in the liver to fuel homeostasis was investigated. Systemic infusion of an adenovirus encoding a dominant negative mutant of PI 3-K (Δp85) resulted in liver-specific expression of this protein and in inhibition of the insulin-induced activation of PI 3-K in the liver within 3 days, without affecting insulin signaling in skeletal muscle. Hepatic expression of Δp85 led to hyperinsulinemia and to a marked increase in blood glucose concentration in response to oral glucose intake. The increases in both glycogen and glucose 6-phosphate content, as well as in Akt and glycogen synthase activities in the liver, that were induced by glucose intake were markedly impaired in mice expressing Δp85. Despite an upregulation of mRNAs for gluconeogenic enzymes apparent in the liver of these animals, the fasting blood glucose concentration was increased only slightly, and the serum concentrations of gluconeogenic precursors were reduced. However, administration of pyruvate, a substrate for gluconeogenesis, resulted in an exaggerated increase in blood glucose concentration. In the fasted state, the mass of adipose tissue of the mice was about 1.5 times that in control mice. The mice also exhibited marked decreases in the serum concentrations of FFAs and triglyceride and suppression of insulin-induced PI 3-K activation in adipose tissue, probably due to the associated hyperinsulinemia. PI 3-K activity in the liver is thus essential for normal carbohydrate and lipid metabolism in living animals.
Compatibility of normal renal function with aging
Authors: J. Lapides
Journal: JAMA (1967)

Serum creatinine and 15-minute phenolsulfonphthalein excretion levels were obtained on 1,000 male and female patients, ranging from 25 to 94 years of age. The renal function tests were used to estimate each patient's glomerular and tubular activity in a quantitative fashion. Correlation of kidney function with the patient's age revealed that one third of the patients 65 years or older had normal glomerular and tubular function. More than two thirds of the elderly individuals demonstrated normal glomerular function.